Helen Tayton-Martin, Chief Business Officer

April 20 | 12:00pm | Gaudi 3 Ballroom

Philadelphia, PA


In-Person Presentation

Adaptimmune, a leader in T cell therapy, has clinical trials ongoing for three wholly owned SPEAR T cells in multiple solid tumor indications. The company’s unique SPEAR T cell platform enables the engineering of T cells to target and destroy cancer, including solid tumors. We have generated a strong pipeline of affinity-enhanced T cell therapies, with multiple INDs open. We use these therapies to harness the body’s own immune system to find and destroy diseased cells. Our SPEAR T cell therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. Adaptimmune partners with industry leaders in all areas of its business.

By using this website you agree to accept our Privacy Policy and Terms & Conditions